Forskning
Udskriv Udskriv
Switch language
Hvidovre Hospital - en del af Københavns Universitetshospital
Udgivet

Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

DOI

  1. Prevalence of Bicuspid Aortic Valve and Associated Aortopathy in Newborns in Copenhagen, Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Association of Office and Ambulatory Blood Pressure With Mortality and Cardiovascular Outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Intensive vs Standard Blood Pressure Control for Older Adults

    Publikation: Bidrag til tidsskriftLetterpeer review

  4. Long-term Recurrence and Complications Associated With Elective Incisional Hernia Repair

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Lung Ultrasound Findings Associated With COVID-19 ARDS, ICU Admission, and All-Cause Mortality

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Reply

    Publikation: Bidrag til tidsskriftLetterpeer review

  3. Testing Denmark: a Danish Nationwide Surveillance Study of COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Marie W Munch
  • Sheila N Myatra
  • Bharath Kumar Tirupakuzhi Vijayaraghavan
  • Sanjith Saseedharan
  • Thomas Benfield
  • Rebecka R Wahlin
  • Bodil S Rasmussen
  • Anne Sofie Andreasen
  • Lone M Poulsen
  • Luca Cioccari
  • Mohd S Khan
  • Farhad Kapadia
  • Jigeeshu V Divatia
  • Anne C Brøchner
  • Morten H Bestle
  • Marie Helleberg
  • Jens Michelsen
  • Ajay Padmanaban
  • Neeta Bose
  • Anders Møller
  • Kapil Borawake
  • Klaus T Kristiansen
  • Urvi Shukla
  • Michelle S Chew
  • Subhal Dixit
  • Charlotte S Ulrik
  • Pravin R Amin
  • Rajesh Chawla
  • Christian A Wamberg
  • Mehul S Shah
  • Iben S Darfelt
  • Vibeke L Jørgensen
  • Margit Smitt
  • Anders Granholm
  • Maj-Brit N Kjær
  • Morten H Møller
  • Tine S Meyhoff
  • Gitte K Vesterlund
  • Naomi E Hammond
  • Sharon Micallef
  • Abhinav Bassi
  • Christian Gluud
  • Klaus V Marcussen
  • Henrik Nielsen
  • Olav L Schjørring
  • Camilla M Kristensen
  • Carl J S Hjortsø
  • Matias Metcalf-Clausen
  • Janus Engstrøm
  • Anders Perner
  • COVID STEROID 2 Trial Group
Vis graf over relationer

Importance: A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in patients with severe and critical COVID-19, but a higher dose may benefit those with more severe disease.

Objective: To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia.

Design, Setting, and Participants: A multicenter, randomized clinical trial was conducted between August 2020 and May 2021 at 26 hospitals in Europe and India and included 1000 adults with confirmed COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation. End of 90-day follow-up was on August 19, 2021.

Interventions: Patients were randomized 1:1 to 12 mg/d of intravenous dexamethasone (n = 503) or 6 mg/d of intravenous dexamethasone (n = 497) for up to 10 days.

Main Outcomes and Measures: The primary outcome was the number of days alive without life support (invasive mechanical ventilation, circulatory support, or kidney replacement therapy) at 28 days and was adjusted for stratification variables. Of the 8 prespecified secondary outcomes, 5 are included in this analysis (the number of days alive without life support at 90 days, the number of days alive out of the hospital at 90 days, mortality at 28 days and at 90 days, and ≥1 serious adverse reactions at 28 days).

Results: Of the 1000 randomized patients, 982 were included (median age, 65 [IQR, 55-73] years; 305 [31%] women) and primary outcome data were available for 971 (491 in the 12 mg of dexamethasone group and 480 in the 6 mg of dexamethasone group). The median number of days alive without life support was 22.0 days (IQR, 6.0-28.0 days) in the 12 mg of dexamethasone group and 20.5 days (IQR, 4.0-28.0 days) in the 6 mg of dexamethasone group (adjusted mean difference, 1.3 days [95% CI, 0-2.6 days]; P = .07). Mortality at 28 days was 27.1% in the 12 mg of dexamethasone group vs 32.3% in the 6 mg of dexamethasone group (adjusted relative risk, 0.86 [99% CI, 0.68-1.08]). Mortality at 90 days was 32.0% in the 12 mg of dexamethasone group vs 37.7% in the 6 mg of dexamethasone group (adjusted relative risk, 0.87 [99% CI, 0.70-1.07]). Serious adverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% in the 12 mg of dexamethasone group vs 13.4% in the 6 mg of dexamethasone group (adjusted relative risk, 0.83 [99% CI, 0.54-1.29]).

Conclusions and Relevance: Among patients with COVID-19 and severe hypoxemia, 12 mg/d of dexamethasone compared with 6 mg/d of dexamethasone did not result in statistically significantly more days alive without life support at 28 days. However, the trial may have been underpowered to identify a significant difference.

Trial Registration: ClinicalTrials.gov Identifier: NCT04509973 and ctri.nic.in Identifier: CTRI/2020/10/028731.

OriginalsprogEngelsk
Artikelnummer18295
TidsskriftJAMA - Journal of the American Medical Association
Vol/bind326
Udgave nummer18
Sider (fra-til)1807-1817
Antal sider11
ISSN0002-9955
DOI
StatusUdgivet - 9 nov. 2021

ID: 68559293